Novo and Pfizer are among the investors set to exit the cancer therapy developer, which has set a $100m target for its initial public offering.

GV-backed Aledade has secured series D funding at a $2.2bn post-money valuation to build out the business model for its primary care network.

Lilly Asia Ventures is the largest shareholder of liver disease therapy developer Terns, which closed a $97.7m round earlier this month.

Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.

Novo and GV participated in a round that lifted the Harvard, Broad Institute and Penn-linked heart disease drug developer's overall funding to more than $215m.

The immunotherapy developer plans to go public in the US having raised $565m since being formed to develop assets of a defunct Oxford spinout.

The Institute for Neurophysiopathology spinout has completed a series D round.

University of Washington spinout AltPep will use the money to advance work on its lead asset that targets Alzheimer’s disease.

PureTech Health, Johnson & Johnson and Novartis are in line for exits after the cancer drug developer filed for its initial public offering.

The immunotherapy developer plans to go public in the United States having raised $565m from investors including Eli Lilly and WuXi AppTec.